Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[1] Currently, there are no FDA-approved targeted therapies for patients with lung cancer who have EGFR Exon 20 insertion mutations.[2]Patients with NSCLC and EGFR Exon 20 insertion mutations have a form of disease that is generally insensitive to EGFR tyrosine kinase inhibitor (TKI) treatments and carries a worse prognosis compared to patients with more common EGFR mutations (Exon 19 deletions/L858R substitution).[3] The current standard of care for this patient population is conventional cytotoxic chemotherapy.[4] “JNJ-6372 is a novel bispecific antibody that we believe has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies,” said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LL...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Adenocarcinoma | Allergy & Immunology | Biotechnology | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiology | Cardiovascular | Chemotherapy | Drugs & Pharmacology | Epithelial Cancer | Food and Drug Administration (FDA) | Genetics | Health Management | Heart | Hypertension | Infectious Diseases | Learning | Legislation | Lung Cancer | Neurology | Neuroscience | Non-Small Cell Lung Cancer | Oral Cancer | Pharmaceuticals | Pulmonary Hypertension | Science | Skin | Skin Cancer | Squamous Cell Carcinoma | Statistics | Study | Universities & Medical Training | Vaccines | Women